Whole-genome sequencing for myeloid disease: one assay to stratify them all?
- PMID: 34011977
- DOI: 10.1038/s41571-021-00522-z
Whole-genome sequencing for myeloid disease: one assay to stratify them all?
Comment on
-
Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.N Engl J Med. 2021 Mar 11;384(10):924-935. doi: 10.1056/NEJMoa2024534. N Engl J Med. 2021. PMID: 33704937 Free PMC article.
References
-
- Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336 (2002). - DOI
-
- Döhner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017). - DOI
-
- De Witte, T. et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel. Blood 129, 1753–1762 (2017). - DOI
-
- Duncavage, E. J. et al. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. N. Engl. J. Med. 384, 924–935 (2021). - DOI
-
- Byrd, J. C. et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J. Clin. Oncol. 17, 3767–3775 (1999). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources